Zura Bio Ltd. Corporate Update: Advancing Tibulizumab, a First-in-Class Bispecific Antibody, into Phase 2 Trials for Major Autoimmune Indications

Key Highlights for Investors

• Lead Asset Tibulizumab: Zura Bio’s lead program, tibulizumab, is the first and only in-class bispecific antibody targeting both the IL-17 and BAFF immune pathways. This innovative approach aims to address complex autoimmune diseases that have not responded optimally to single-pathway therapies.
• Clinical Pipeline Progress: Two Phase 2 clinical trials are ongoing:
  • Hidradenitis Suppurativa (HS): Topline data expected Q4 2026
  • Systemic Sclerosis (SSc): Topline data expected in the first half of 2027
• Financial Strength: Zura Bio is well-capitalized following a recent public offering in February 2026, with \$109M in cash as of December 31, 2025, plus \$144M in gross proceeds. The company expects this funding to support operations through at least the end of 2028.
• Share Structure: Following the February 2026 offering, Zura Bio has approximately 124 million shares outstanding (as-converted), not including potential dilution from employee options and RSUs.
• Executive Leadership: The company is led by an experienced board and executive team, including CEO & Co-Founder Dr. Sandeep Kulkarni, and Chairman Amit Munshi.

Details of Tibulizumab: Differentiated Approach for Complex Immune Disorders

• Mechanism: Tibulizumab fuses elements of tabalumab (a BAFF-binding antibody) with an IL-17–binding variable fragment derived from ixekizumab (Taltz®, with over \$3.6B in 2024 global sales).
• Dual Inhibition: The antibody blocks both the BAFF and IL-17 (including IL-17A and IL-17A/F heterodimers) pathways, aiming to modulate both B-cell and T-cell driven disease processes.
• Rationale: Dual inhibition is designed to overcome the “efficacy ceiling” seen with single-pathway agents, especially in diseases with complex, redundant, or compensatory immune signaling.
• Initial Indications:
  • HS: Highly heterogeneous, relapsing inflammatory skin disease. Potential for best-in-class efficacy by targeting both validated pathways.
  • SSc: Rare, severe, multisystem autoimmune disease; tibulizumab could be the first therapy to address both skin and lung manifestations.
• Phase 1 Data: Over 98% median trough target engagement for both IL-17 and BAFF was observed, with favorable pharmacokinetic/pharmacodynamic (PK/PD) and safety profiles. No new or unexpected safety signals emerged.

Market Opportunity: Multi-Billion Dollar Potential

• Hidradenitis Suppurativa (HS): Estimated total addressable market (TAM) of ~\$8B by the mid-2030s. The disease is underdiagnosed, causes substantial morbidity, and is not fully addressed by current biologics.
• Systemic Sclerosis (SSc): Estimated TAM of ~\$4B by the mid-2030s. There are no approved therapies that comprehensively address the multisystem pathology of SSc. SSc affects approximately 300,000 patients across major markets.

Key Clinical and Competitive Insights

• Limitations of Current Therapies: Most autoimmune diseases, including HS and SSc, are driven by multiple immune pathways. Existing single-pathway biologics often yield suboptimal response rates due to biological heterogeneity and pathway redundancy.
• Tibulizumab’s Advantage: As a single molecule targeting two pathways, tibulizumab offers dual-pathway modulation without the complexity of combination therapies.
• Clinical Precedent: Both IL-17 and BAFF inhibition have shown efficacy in placebo-controlled trials for SSc and HS. For example, brodalumab (IL-17 receptor antagonist) met the primary endpoint in SSc, while belimumab (BAFF antagonist) showed improvements in skin and quality of life measures in a pilot study.
• Competitive Landscape: The HS market features multiple approved and late-stage therapies (e.g., adalimumab, secukinumab, bimekizumab, remibrutinib), but no agent to date targets both BAFF and IL-17. Tibulizumab is positioned as the only dual-pathway agent in clinical development for these indications.

Phase 2 Study Designs: What to Watch

Hidradenitis Suppurativa (TibuSHIELD Study)

• Randomized, double-blind, placebo-controlled, three-arm study
• Up to 225 participants with moderate-to-severe HS (Hurley Stage II/III)
• Primary Endpoint: Percent change from baseline in abscess and inflammatory nodule count at Week 16
• Two dose arms (150 mg and 300 mg SC), with dose selection informed by Phase 1 PK/PD data
• 16-week primary efficacy period, followed by a 16-week open-label extension
• Topline data expected Q4 2026

Systemic Sclerosis (TibuSURE Study)

• Randomized, double-blind, placebo-controlled study in early diffuse cutaneous SSc, enriched for SSc-ILD
• Primary Endpoint: Change from baseline in modified Rodnan Skin Score (mRSS) at Week 24
• Key secondary endpoints: Quantitative high-resolution CT imaging, FVC, HAQ-DI, revised CRISS, patient- and clinician-reported outcomes
• 28-week open-label extension after 24-week primary period
• Topline data expected in 1H 2027

Other Potentially Price-Sensitive Details

• Near-Term Catalysts: Investors should closely monitor topline readouts from Phase 2 studies in HS (Q4 2026) and SSc (1H 2027). Favorable results could significantly de-risk the program and drive share price appreciation.
• Balance Sheet Strength: The recent financing ensures Zura Bio is funded beyond these key inflection points, reducing financial risk and supporting continued R&D investment.
• Dilution Risk: The increased share count following the February 2026 offering (~124 million shares) may impact per-share metrics and should be considered by current and prospective shareholders.
• Platform Potential: If tibulizumab proves effective, the company may expand into additional autoimmune indications, representing a broader and longer-term growth opportunity.

Risks & Forward-Looking Considerations

• Zura Bio has no products approved for commercial sale and has not completed any pivotal clinical trials. Substantial additional capital may be required to advance products to approval and commercialization.
• The company is dependent on third-party manufacturers and research organizations for clinical development.
• Success is not assured—delays, regulatory setbacks, or negative trial results could materially impact share value.
• Forward-looking statements are based on current assumptions and are subject to significant risks and uncertainties.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties. Investors should consult official SEC filings and conduct their own due diligence before making investment decisions.

View Zura Bio Ltd Historical chart here